25 XP   0   0   10

Alimera Sciences Inc
Buy, Hold or Sell?

Let's analyse Alimera Sciences Inc together

PenkeI guess you are interested in Alimera Sciences Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Alimera Sciences Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Alimera Sciences Inc

I send you an email if I find something interesting about Alimera Sciences Inc.

Quick analysis of Alimera Sciences Inc (30 sec.)










What can you expect buying and holding a share of Alimera Sciences Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
5.0%

What is your share worth?

Current worth
$0.85
Expected worth in 1 year
$2.09
How sure are you?
27.5%

+ What do you gain per year?

Total Gains per Share
$1.25
Return On Investment
34.7%

For what price can you sell your share?

Current Price per Share
$3.59
Expected price per share
$2.9314 - $4.25
How sure are you?
50%

1. Valuation of Alimera Sciences Inc (5 min.)




Live pricePrice per Share (EOD)

$3.59

Intrinsic Value Per Share

$-1.52 - $0.22

Total Value Per Share

$-0.67 - $1.07

2. Growth of Alimera Sciences Inc (5 min.)




Is Alimera Sciences Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$46.1m-$14.9m$45.5m148.9%

How much money is Alimera Sciences Inc making?

Current yearPrevious yearGrowGrow %
Making money-$5.8m-$4.9m-$887.5k-15.1%
Net Profit Margin-34.7%-38.0%--

How much money comes from the company's main activities?

3. Financial Health of Alimera Sciences Inc (5 min.)




What can you expect buying and holding a share of Alimera Sciences Inc? (5 min.)

Welcome investor! Alimera Sciences Inc's management wants to use your money to grow the business. In return you get a share of Alimera Sciences Inc.

What can you expect buying and holding a share of Alimera Sciences Inc?

First you should know what it really means to hold a share of Alimera Sciences Inc. And how you can make/lose money.

Speculation

The Price per Share of Alimera Sciences Inc is $3.59. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Alimera Sciences Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Alimera Sciences Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.85. Based on the TTM, the Book Value Change Per Share is $0.31 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.09 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Alimera Sciences Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.07-1.9%-0.13-3.5%-0.12-3.3%-0.07-1.9%-0.08-2.3%
Usd Book Value Change Per Share-0.08-2.4%0.318.7%-0.09-2.4%0.041.1%0.020.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.020.7%
Usd Total Gains Per Share-0.08-2.4%0.318.7%-0.09-2.4%0.041.1%0.051.3%
Usd Price Per Share4.32-3.11-4.72-4.44-3.57-
Price to Earnings Ratio-15.55--12.91--12.81--9.86--5.52-
Price-to-Total Gains Ratio-51.11-17.58--55.79--185.26--3.37-
Price to Book Ratio5.09-1.48--19.70--7.72-1.18-
Price-to-Total Gains Ratio-51.11-17.58--55.79--185.26--3.37-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.59
Number of shares278
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.310.04
Usd Total Gains Per Share0.310.04
Gains per Quarter (278 shares)86.6411.07
Gains per Year (278 shares)346.5444.28
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1034733704434
2069368408978
30104010310133122
40138613780177166
50173317250221210
60207920720266254
70242624190310298
80277227660354342
90311931130399386
100346534600443430

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%2.018.00.010.0%4.036.00.010.0%5.059.00.07.8%
Book Value Change Per Share3.01.00.075.0%4.08.00.033.3%5.015.00.025.0%11.029.00.027.5%14.047.03.021.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%2.00.038.05.0%3.00.061.04.7%
Total Gains per Share3.01.00.075.0%4.08.00.033.3%5.015.00.025.0%11.029.00.027.5%14.047.03.021.9%

Fundamentals of Alimera Sciences Inc

About Alimera Sciences Inc

Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Fundamental data was last updated by Penke on 2024-04-11 00:09:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Alimera Sciences Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Alimera Sciences Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Alimera Sciences Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -14.4% means that $-0.14 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Alimera Sciences Inc:

  • The MRQ is -14.4%. The company is making a huge loss. -2
  • The TTM is -34.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-14.4%TTM-34.7%+20.3%
TTM-34.7%YOY-38.0%+3.4%
TTM-34.7%5Y-24.4%-10.3%
5Y-24.4%10Y-92.6%+68.3%
1.1.2. Return on Assets

Shows how efficient Alimera Sciences Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Alimera Sciences Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • -2.5% Return on Assets means that Alimera Sciences Inc generated $-0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Alimera Sciences Inc:

  • The MRQ is -2.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -6.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.5%TTM-6.8%+4.3%
TTM-6.8%YOY-10.8%+4.0%
TTM-6.8%5Y-5.6%-1.2%
5Y-5.6%10Y-8.0%+2.5%
1.1.3. Return on Equity

Shows how efficient Alimera Sciences Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Alimera Sciences Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • -8.2% Return on Equity means Alimera Sciences Inc generated $-0.08 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Alimera Sciences Inc:

  • The MRQ is -8.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -8.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-8.2%TTM-8.2%0.0%
TTM-8.2%YOY--8.2%
TTM-8.2%5Y-30.5%+22.4%
5Y-30.5%10Y-40.5%+9.9%

1.2. Operating Efficiency of Alimera Sciences Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Alimera Sciences Inc is operating .

  • Measures how much profit Alimera Sciences Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Alimera Sciences Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 4.5% means the company generated $0.05  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Alimera Sciences Inc:

  • The MRQ is 4.5%. The company is operating less efficient.
  • The TTM is -10.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ4.5%TTM-10.4%+14.9%
TTM-10.4%YOY-22.1%+11.7%
TTM-10.4%5Y-10.6%+0.2%
5Y-10.6%10Y-86.5%+75.9%
1.2.2. Operating Ratio

Measures how efficient Alimera Sciences Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.95 means that the operating costs are $0.95 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Alimera Sciences Inc:

  • The MRQ is 0.955. The company is less efficient in keeping operating costs low.
  • The TTM is 1.018. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ0.955TTM1.018-0.063
TTM1.018YOY1.221-0.204
TTM1.0185Y1.089-0.071
5Y1.08910Y1.802-0.713

1.3. Liquidity of Alimera Sciences Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Alimera Sciences Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 2.39 means the company has $2.39 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Alimera Sciences Inc:

  • The MRQ is 2.392. The company is able to pay all its short-term debts. +1
  • The TTM is 2.718. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.392TTM2.718-0.326
TTM2.718YOY1.240+1.478
TTM2.7185Y2.675+0.043
5Y2.67510Y3.832-1.157
1.3.2. Quick Ratio

Measures if Alimera Sciences Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Alimera Sciences Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 2.13 means the company can pay off $2.13 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Alimera Sciences Inc:

  • The MRQ is 2.128. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.410. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.128TTM2.410-0.282
TTM2.410YOY1.037+1.373
TTM2.4105Y2.295+0.115
5Y2.29510Y3.418-1.124

1.4. Solvency of Alimera Sciences Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Alimera Sciences Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Alimera Sciences Inc to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.70 means that Alimera Sciences Inc assets are financed with 69.9% credit (debt) and the remaining percentage (100% - 69.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Alimera Sciences Inc:

  • The MRQ is 0.699. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.869. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.699TTM0.869-0.170
TTM0.869YOY1.334-0.465
TTM0.8695Y1.093-0.224
5Y1.09310Y0.910+0.183
1.4.2. Debt to Equity Ratio

Measures if Alimera Sciences Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Alimera Sciences Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 232.5% means that company has $2.33 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Alimera Sciences Inc:

  • The MRQ is 2.325. The company is just not able to pay all its debts with equity.
  • The TTM is 1.708. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ2.325TTM1.708+0.617
TTM1.708YOY-+1.708
TTM1.7085Y6.767-5.059
5Y6.76710Y5.693+1.074

2. Market Valuation of Alimera Sciences Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Alimera Sciences Inc generates.

  • Above 15 is considered overpriced but always compare Alimera Sciences Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -15.55 means the investor is paying $-15.55 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Alimera Sciences Inc:

  • The EOD is -12.918. Based on the earnings, the company is expensive. -2
  • The MRQ is -15.545. Based on the earnings, the company is expensive. -2
  • The TTM is -12.913. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-12.918MRQ-15.545+2.627
MRQ-15.545TTM-12.913-2.632
TTM-12.913YOY-12.814-0.099
TTM-12.9135Y-9.863-3.050
5Y-9.86310Y-5.524-4.339
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Alimera Sciences Inc:

  • The EOD is 13.255. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 15.950. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is -0.260. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD13.255MRQ15.950-2.695
MRQ15.950TTM-0.260+16.210
TTM-0.260YOY-49.499+49.240
TTM-0.2605Y-10.850+10.591
5Y-10.85010Y-7.963-2.887
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Alimera Sciences Inc is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Alimera Sciences Inc:

  • The EOD is 4.232. Based on the equity, the company is fair priced.
  • The MRQ is 5.092. Based on the equity, the company is overpriced. -1
  • The TTM is 1.477. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD4.232MRQ5.092-0.860
MRQ5.092TTM1.477+3.615
TTM1.477YOY-19.703+21.181
TTM1.4775Y-7.717+9.194
5Y-7.71710Y1.178-8.895
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Alimera Sciences Inc.

3.1. Institutions holding Alimera Sciences Inc

Institutions are holding 91.96% of the shares of Alimera Sciences Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Caligan Partners LP32.156124.52691683515400
2023-12-31Velan Capital Investment Management LP25.993134.31381360853300
2023-12-31Stonepine Capital Management Llc7.63927.47213999459157730.3959
2023-12-31BOOTHBAY FUND MANAGEMENT, LLC6.10970.3527319870800
2023-12-31Altium Capital Management, LP5.08087.80072660000-274108-9.3421
2023-12-31AIGH Capital Management, LLC4.25193.80452226068-146504-6.1749
2023-12-31Clearline Capital LP4.14320.57422169143-166150-7.1147
2023-12-31Morgan Stanley - Brokerage Accounts1.75010.000491624625000037.5237
2023-12-31Vanguard Group Inc1.23950.0001648954502268342.4103
2023-12-31Worth Venture Partners, LLC1.06321.2996556642-37067-6.2433
2023-12-31BlackRock Inc0.84780.000144383944330482860.5607
2023-12-31Geode Capital Management, LLC0.63410.0002331977279153528.4587
2023-12-31Renaissance Technologies Corp0.30330.00111587944590040.6576
2023-12-31Bank of Montreal0.23740.00021242971242970
2023-12-31BMO Capital Markets Corp.0.23740.00021242971242970
2023-12-31Susquehanna International Group, LLP0.21130.00011106101106100
2023-12-31Balyasny Asset Management LLC0.07650.000340032400320
2023-12-31Millennium Management LLC0.0620.000132461-57350-63.8563
2023-12-31Citigroup Inc0.05880.000130808292081825.5
2023-12-31HighTower Advisors, LLC0.04790.000225091250910
Total 92.143380.147648241113+1308754+2.7%

3.2. Funds holding Alimera Sciences Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.02950.001953898000
2024-02-29Vanguard Total Stock Mkt Idx Inv0.94390.000149419400
2023-12-31HBM Healthcare Investments AG Ord0.89140.10146666600
2024-02-29Fidelity Extended Market Index0.38880.0019203529-986-0.4821
2024-03-31Ancora/Thelen Small-Mid Cap I0.19670.22651030001030000
2024-03-31BlackRock Extended Equity Market K0.13920.00272869728690
2024-02-29Fidelity Series Total Market Index0.10860.000356843-4058-6.6633
2024-02-29Fidelity Total Market Index0.09710.00025081600
2024-02-29Fidelity Nasdaq Composite Index0.05130.000626883332714.1238
2024-02-29Spartan Total Market Index Pool E0.04980.00032609400
2023-12-31Bridgeway Ultra-Small Company Market0.03820.04652000000
2024-03-31State St US Extended Mkt Indx NL Cl C0.03680.003919271189005094.3396
2024-02-29Spartan Extended Market Index Pool E0.02630.002137709867.7128
2024-02-29Vanguard U.S. Eq Idx £ Acc0.02350.000212286-10294-45.589
2023-12-31Northern Trust Extended Eq Market Idx0.02140.0008111877500203.4174
2023-12-31NT Ext Equity Mkt Idx Fd - L0.02140.0008111877500203.4174
2024-03-31Extended Equity Market Fund M0.01720.002898989890
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.0050.0002264300
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.00410.0002212340.1888
2024-02-29State St US Ttl Mkt Indx SL Cl I0.001050000
Total 4.09120.39142141830+207737+9.7%

3.3. Insider Transactions

Insiders are holding 8.774% of the shares of Alimera Sciences Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-09-14Caligan Partners LpBUY5790003.39
2023-05-17Adam MorganBUY14019011.7

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Alimera Sciences Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.0850.312-127%-0.087+3%0.040-312%0.024-459%
Book Value Per Share--0.8480.576+47%-0.286+134%0.011+7953%0.195+335%
Current Ratio--2.3922.718-12%1.240+93%2.675-11%3.832-38%
Debt To Asset Ratio--0.6990.869-20%1.334-48%1.093-36%0.910-23%
Debt To Equity Ratio--2.3251.708+36%-+100%6.767-66%5.693-59%
Dividend Per Share----0%-0%-0%0.024-100%
Eps---0.069-0.126+81%-0.119+72%-0.068-2%-0.082+18%
Free Cash Flow Per Share--0.068-0.429+734%-0.049+172%-0.106+257%-0.123+281%
Free Cash Flow To Equity Per Share--0.0660.031+111%-0.050+176%0.000+101%0.000+13630%
Gross Profit Margin--3.0543.315-8%2.462+24%2.518+21%2.319+32%
Intrinsic Value_10Y_max--0.219--------
Intrinsic Value_10Y_min---1.519--------
Intrinsic Value_1Y_max---0.418--------
Intrinsic Value_1Y_min---0.579--------
Intrinsic Value_3Y_max---0.920--------
Intrinsic Value_3Y_min---1.381--------
Intrinsic Value_5Y_max---1.018--------
Intrinsic Value_5Y_min---1.782--------
Market Cap187952296.000-25%235107208.800165056234.200+42%246850996.000-5%233021546.476+1%186935817.942+26%
Net Profit Margin---0.144-0.347+141%-0.380+165%-0.244+70%-0.926+545%
Operating Margin--0.045-0.104+331%-0.221+591%-0.106+335%-0.865+2020%
Operating Ratio--0.9551.018-6%1.221-22%1.089-12%1.802-47%
Pb Ratio4.232-20%5.0921.477+245%-19.703+487%-7.717+252%1.178+332%
Pe Ratio-12.918+17%-15.545-12.913-17%-12.814-18%-9.863-37%-5.524-64%
Price Per Share3.590-20%4.3203.110+39%4.715-8%4.442-3%3.566+21%
Price To Free Cash Flow Ratio13.255-20%15.950-0.260+102%-49.499+410%-10.850+168%-7.963+150%
Price To Total Gains Ratio-42.476+17%-51.11417.581-391%-55.787+9%-185.264+262%-3.367-93%
Quick Ratio--2.1282.410-12%1.037+105%2.295-7%3.418-38%
Return On Assets---0.025-0.068+174%-0.108+337%-0.056+127%-0.080+227%
Return On Equity---0.082-0.0820%--100%-0.305+273%-0.405+394%
Total Gains Per Share---0.0850.312-127%-0.087+3%0.040-312%0.048-278%
Usd Book Value--46170000.00030581000.000+51%-14966000.000+132%639300.000+7122%10249225.000+350%
Usd Book Value Change Per Share---0.0850.312-127%-0.087+3%0.040-312%0.024-459%
Usd Book Value Per Share--0.8480.576+47%-0.286+134%0.011+7953%0.195+335%
Usd Dividend Per Share----0%-0%-0%0.024-100%
Usd Eps---0.069-0.126+81%-0.119+72%-0.068-2%-0.082+18%
Usd Free Cash Flow--3685000.000-22448250.000+709%-2557500.000+169%-5550350.000+251%-6427250.000+274%
Usd Free Cash Flow Per Share--0.068-0.429+734%-0.049+172%-0.106+257%-0.123+281%
Usd Free Cash Flow To Equity Per Share--0.0660.031+111%-0.050+176%0.000+101%0.000+13630%
Usd Market Cap187952296.000-25%235107208.800165056234.200+42%246850996.000-5%233021546.476+1%186935817.942+26%
Usd Price Per Share3.590-20%4.3203.110+39%4.715-8%4.442-3%3.566+21%
Usd Profit---3781000.000-5866250.000+55%-4978750.000+32%-3176700.000-16%-5041175.000+33%
Usd Revenue--26306000.00020188500.000+30%13532250.000+94%14933750.000+76%11168775.000+136%
Usd Total Gains Per Share---0.0850.312-127%-0.087+3%0.040-312%0.048-278%
 EOD+4 -4MRQTTM+21 -13YOY+27 -75Y+22 -1210Y+24 -12

4.2. Fundamental Score

Let's check the fundamental score of Alimera Sciences Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-12.918
Price to Book Ratio (EOD)Between0-14.232
Net Profit Margin (MRQ)Greater than0-0.144
Operating Margin (MRQ)Greater than00.045
Quick Ratio (MRQ)Greater than12.128
Current Ratio (MRQ)Greater than12.392
Debt to Asset Ratio (MRQ)Less than10.699
Debt to Equity Ratio (MRQ)Less than12.325
Return on Equity (MRQ)Greater than0.15-0.082
Return on Assets (MRQ)Greater than0.05-0.025
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Alimera Sciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.276
Ma 20Greater thanMa 503.723
Ma 50Greater thanMa 1003.716
Ma 100Greater thanMa 2003.763
OpenGreater thanClose3.573
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Accumulated Other Comprehensive Income  -2,995212-2,7830-2,783-211-2,9944,6841,690
EBIT  -2,108-1,194-3,3022,094-1,208-2,269-3,4774,6621,185



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets153,524
Total Liabilities107,354
Total Stockholder Equity46,170
 As reported
Total Liabilities 107,354
Total Stockholder Equity+ 46,170
Total Assets = 153,524

Assets

Total Assets153,524
Total Current Assets52,423
Long-term Assets101,101
Total Current Assets
Cash And Cash Equivalents 12,090
Net Receivables 34,545
Inventory 1,879
Other Current Assets 3,909
Total Current Assets  (as reported)52,423
Total Current Assets  (calculated)52,423
+/-0
Long-term Assets
Property Plant Equipment 3,590
Long-term Assets Other 52
Long-term Assets  (as reported)101,101
Long-term Assets  (calculated)3,642
+/- 97,459

Liabilities & Shareholders' Equity

Total Current Liabilities21,913
Long-term Liabilities85,441
Total Stockholder Equity46,170
Total Current Liabilities
Short-term Debt 828
Accounts payable 8,252
Other Current Liabilities 12,833
Total Current Liabilities  (as reported)21,913
Total Current Liabilities  (calculated)21,913
+/-0
Long-term Liabilities
Long term Debt 64,489
Capital Lease Obligations 828
Long-term Liabilities Other 5,816
Long-term Liabilities  (as reported)85,441
Long-term Liabilities  (calculated)71,133
+/- 14,308
Total Stockholder Equity
Common Stock524
Retained Earnings -418,490
Accumulated Other Comprehensive Income 1,690
Other Stockholders Equity 458,574
Total Stockholder Equity (as reported)46,170
Total Stockholder Equity (calculated)42,298
+/- 3,872
Other
Capital Stock524
Cash and Short Term Investments 12,090
Common Stock Shares Outstanding 54,423
Liabilities and Stockholders Equity 153,524
Net Debt 55,309
Net Invested Capital 110,659
Net Working Capital 30,510
Property Plant and Equipment Gross 7,991
Short Long Term Debt Total 67,399



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-06-302007-03-31
> Total Assets 
0
0
24,519
35,394
34,076
0
20,264
0
0
10,889
16,561
16,251
61,528
55,772
56,414
51,233
45,874
40,294
34,698
28,710
23,735
19,826
52,521
43,194
37,855
30,536
19,620
47,418
48,658
93,291
109,412
96,835
87,329
79,013
70,484
62,000
58,766
74,980
70,229
62,590
65,873
64,758
59,924
56,117
54,835
51,202
54,108
52,310
50,242
46,729
50,309
48,998
49,094
49,080
50,855
45,587
62,102
60,065
58,520
49,931
47,574
43,429
42,602
48,239
154,923
154,192
153,524
153,524154,192154,92348,23942,60243,42947,57449,93158,52060,06562,10245,58750,85549,08049,09448,99850,30946,72950,24252,31054,10851,20254,83556,11759,92464,75865,87362,59070,22974,98058,76662,00070,48479,01387,32996,835109,41293,29148,65847,41819,62030,53637,85543,19452,52119,82623,73528,71034,69840,29445,87451,23356,41455,77261,52816,25116,56110,8890020,264034,07635,39424,51900
   > Total Current Assets 
0
0
0
34,853
33,403
0
19,468
0
0
10,592
16,307
16,022
61,291
55,510
56,194
51,053
45,653
40,076
34,501
28,539
23,580
19,694
52,407
43,079
37,386
30,104
18,638
46,459
47,535
67,298
83,269
70,313
61,142
53,388
45,159
37,212
34,664
51,603
47,402
40,450
44,280
43,602
39,322
35,858
34,577
31,412
34,848
32,873
30,913
28,108
32,745
32,145
32,471
32,613
34,906
30,330
45,237
43,633
42,160
34,753
33,073
29,760
29,413
35,675
46,022
48,402
52,423
52,42348,40246,02235,67529,41329,76033,07334,75342,16043,63345,23730,33034,90632,61332,47132,14532,74528,10830,91332,87334,84831,41234,57735,85839,32243,60244,28040,45047,40251,60334,66437,21245,15953,38861,14270,31383,26967,29847,53546,45918,63830,10437,38643,07952,40719,69423,58028,53934,50140,07645,65351,05356,19455,51061,29116,02216,30710,5920019,468033,40334,853000
       Cash And Cash Equivalents 
0
0
0
33,053
30,985
0
17,875
0
0
9,902
14,858
14,178
45,635
14,711
28,514
49,457
43,932
38,107
33,108
27,625
22,291
17,355
49,564
39,307
31,925
23,104
12,628
41,326
41,986
61,424
76,697
61,328
48,136
39,340
31,075
23,940
16,627
33,853
30,979
26,737
26,882
25,624
24,067
20,253
16,687
12,591
13,043
13,094
12,157
7,903
9,426
12,242
13,496
11,254
11,208
8,266
24,780
21,524
16,510
9,946
7,859
5,514
5,274
13,086
18,775
8,285
12,090
12,0908,28518,77513,0865,2745,5147,8599,94616,51021,52424,7808,26611,20811,25413,49612,2429,4267,90312,15713,09413,04312,59116,68720,25324,06725,62426,88226,73730,97933,85316,62723,94031,07539,34048,13661,32876,69761,42441,98641,32612,62823,10431,92539,30749,56417,35522,29127,62533,10838,10743,93249,45728,51414,71145,63514,17814,8589,9020017,875030,98533,053000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
14,544
39,966
26,330
503
502
502
500
500
0
0
0
0
0
0
0
0
0
0
0
0
0
0
37
39
38
38
31
31
33
34
34
35
33
33
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000003333353434333131383839370000000000000050050050250250326,33039,96614,544000000000000
       Net Receivables 
0
0
0
0
29
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
95
74
129
464
500
1,278
1,020
1,097
850
3,423
7,732
9,377
9,799
9,078
13,257
13,397
13,839
10,768
13,648
13,454
11,435
12,354
13,419
14,280
17,259
15,417
13,892
16,377
19,331
16,179
14,034
15,628
17,200
15,702
15,086
16,210
19,128
18,776
20,319
19,142
19,612
18,433
22,589
33,943
34,545
34,54533,94322,58918,43319,61219,14220,31918,77619,12816,21015,08615,70217,20015,62814,03416,17919,33116,37713,89215,41717,25914,28013,41912,35411,43513,45413,64810,76813,83913,39713,2579,0789,7999,3777,7323,4238501,0971,0201,278500464129749500000000000000000290000
       Other Current Assets 
0
0
1,262
1,800
2,389
0
1,593
0
0
690
1,449
1,844
1,112
833
272
1,093
1,219
1,467
893
914
1,083
1,668
2,029
2,640
3,206
3,220
3,474
2,413
2,560
2,245
3,234
2,913
3,104
2,497
2,696
2,796
3,532
3,402
2,107
2,112
2,574
2,752
2,278
1,992
2,299
2,787
2,109
2,469
2,691
2,155
2,565
2,497
2,942
3,177
3,718
3,736
3,029
3,564
3,809
3,546
3,208
3,290
2,892
2,910
3,571
4,383
3,909
3,9094,3833,5712,9102,8923,2903,2083,5463,8093,5643,0293,7363,7183,1772,9422,4972,5652,1552,6912,4692,1092,7872,2991,9922,2782,7522,5742,1122,1073,4023,5322,7962,6962,4973,1042,9133,2342,2452,5602,4133,4743,2203,2062,6402,0291,6681,0839148931,4671,2191,0932728331,1121,8441,449690001,59302,3891,8001,26200
   > Long-term Assets 
0
0
0
541
673
0
796
0
0
297
254
229
237
262
220
180
221
218
197
171
155
132
114
115
469
432
982
959
1,123
25,993
26,143
26,522
26,187
25,625
25,325
24,788
24,102
23,377
22,827
22,140
21,593
21,156
20,602
20,259
20,258
19,790
19,260
19,437
19,329
18,621
17,564
16,853
16,623
16,467
15,949
15,257
16,865
16,432
16,360
15,178
14,501
13,669
13,189
12,564
108,901
105,790
101,101
101,101105,790108,90112,56413,18913,66914,50115,17816,36016,43216,86515,25715,94916,46716,62316,85317,56418,62119,32919,43719,26019,79020,25820,25920,60221,15621,59322,14022,82723,37724,10224,78825,32525,62526,18726,52226,14325,9931,123959982432469115114132155171197218221180220262237229254297007960673541000
       Property Plant Equipment 
0
0
397
517
649
0
796
0
0
297
254
229
237
262
220
180
221
218
197
171
155
132
114
115
469
432
982
959
1,123
1,042
1,653
2,511
2,659
2,587
2,553
2,489
2,293
2,054
1,787
1,572
1,477
1,514
1,410
1,531
1,542
1,570
1,355
2,034
2,394
2,222
2,047
1,834
2,072
2,373
2,358
2,178
2,199
3,383
4,493
4,343
3,938
3,870
3,920
3,757
3,742
3,618
3,590
3,5903,6183,7423,7573,9203,8703,9384,3434,4933,3832,1992,1782,3582,3732,0721,8342,0472,2222,3942,0341,3551,5701,5421,5311,4101,5141,4771,5721,7872,0542,2932,4892,5532,5872,6592,5111,6531,0421,12395998243246911511413215517119721822118022026223722925429700796064951739700
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
24,951
24,490
24,011
23,528
23,038
22,549
22,066
21,582
21,093
20,604
20,125
19,642
19,153
18,664
18,185
17,701
17,212
16,723
16,245
15,761
15,272
14,783
14,299
13,816
13,327
12,838
0
0
0
0
0
0
0
0
0
0
0
0
00000000000012,83813,32713,81614,29914,78315,27215,76116,24516,72317,21217,70118,18518,66419,15319,64220,12520,60421,09321,58222,06622,54923,03823,52824,01124,49024,95100000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
24,951
24,490
24,011
23,528
23,038
22,549
22,066
21,582
21,093
20,604
20,125
19,642
19,153
18,664
18,185
17,701
17,212
16,723
16,245
15,761
15,272
14,783
14,299
13,816
13,327
12,838
12,359
11,875
11,386
10,897
10,419
9,935
9,446
8,957
8,479
104,935
101,975
0
0101,975104,9358,4798,9579,4469,93510,41910,89711,38611,87512,35912,83813,32713,81614,29914,78315,27215,76116,24516,72317,21217,70118,18518,66419,15319,64220,12520,60421,09321,58222,06622,54923,03823,52824,01124,49024,95100000000000000000000000000000
       Other Assets 
0
0
24
24
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
24,951
24,490
24,011
23,528
23,038
22,772
22,299
21,809
21,323
21,040
20,568
20,116
19,642
19,192
543
1,015
1,008
1,182
1,158
1,174
1,127
734
720
735
1,558
1,473
720
2,791
1,663
970
416
628
353
0
0
224
0
0
00224003536284169701,6632,7917201,4731,5587357207341,1271,1741,1581,1821,0081,01554319,19219,64220,11620,56821,04021,32321,80922,29922,77223,03823,52824,01124,49024,9510000000000000000000000000242400
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
223
233
227
230
0
443
474
489
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000048947444302302272332230000000000000000000000000000000000
> Total Liabilities 
0
0
0
117,863
123,772
0
136,151
0
0
152,065
21,943
182,746
5,230
5,328
11,202
10,168
9,224
9,709
9,720
7,741
6,884
8,029
13,377
17,458
27,884
21,338
24,545
36,767
34,999
85,068
59,893
56,263
53,998
45,652
44,164
45,107
46,963
44,948
44,643
42,524
44,171
43,994
45,005
47,566
49,297
48,231
51,386
51,664
53,924
53,205
54,754
54,402
56,624
56,713
58,833
57,547
56,211
58,563
61,125
58,534
59,909
61,507
63,450
67,155
108,693
105,352
107,354
107,354105,352108,69367,15563,45061,50759,90958,53461,12558,56356,21157,54758,83356,71356,62454,40254,75453,20553,92451,66451,38648,23149,29747,56645,00543,99444,17142,52444,64344,94846,96345,10744,16445,65253,99856,26359,89385,06834,99936,76724,54521,33827,88417,45813,3778,0296,8847,7419,7209,7099,22410,16811,2025,3285,230182,74621,943152,06500136,1510123,772117,863000
   > Total Current Liabilities 
0
0
4,236
5,115
6,845
0
4,917
0
0
9,031
10,735
12,544
5,205
5,305
6,417
5,991
5,212
6,199
6,718
5,253
4,917
6,586
12,465
17,070
7,208
7,314
4,949
4,462
4,215
31,986
10,475
11,990
14,971
6,737
39,933
42,408
45,188
7,853
9,123
6,777
9,577
9,004
9,671
7,465
8,980
7,707
10,234
9,973
11,590
14,235
12,048
9,121
10,139
10,235
12,348
11,209
10,308
11,399
12,592
17,006
25,431
34,010
39,732
14,173
14,245
17,721
21,913
21,91317,72114,24514,17339,73234,01025,43117,00612,59211,39910,30811,20912,34810,23510,1399,12112,04814,23511,5909,97310,2347,7078,9807,4659,6719,0049,5776,7779,1237,85345,18842,40839,9336,73714,97111,99010,47531,9864,2154,4624,9497,3147,20817,07012,4656,5864,9175,2536,7186,1995,2125,9916,4175,3055,20512,54410,7359,031004,91706,8455,1154,23600
       Short-term Debt 
0
0
0
11
11
0
10
0
0
3,006
4,506
6,005
10
10
1,168
1,863
2,094
2,397
2,474
2,474
2,360
2,471
2,279
2,351
1,120
1,537
1,677
1,677
10
10
1,034
4,725
204
218
32,020
33,879
34,054
235
191
157
137
187
184
216
211
237
236
253
247
3,591
255
243
1,115
1,404
1,690
1,993
301
289
489
7,356
14,501
21,643
25,646
263
203
193
828
82819320326325,64621,64314,5017,3564892893011,9931,6901,4041,1152432553,59124725323623721121618418713715719123534,05433,87932,0202182044,7251,03410101,6771,6771,5371,1202,3512,2792,4712,3602,4742,4742,3972,0941,8631,16810106,0054,5063,006001001111000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,023
0
0
0
31,786
0
0
0
33,549
178
33,958
34,402
34,752
37,753
38,010
0
0
433
0
3,333
0
0
889
1,185
1,481
1,778
0
0
0
7,105
14,211
21,316
25,313
0
0
0
0
000025,31321,31614,2117,1050001,7781,4811,185889003,33304330038,01037,75334,75234,40233,95817833,54900031,7860001,023000000000000000000000000000000
       Accounts payable 
0
0
845
980
2,190
0
1,575
0
0
1,379
1,758
1,940
1,457
1,517
1,677
2,013
1,431
1,950
1,948
1,656
1,279
1,702
1,973
2,340
3,195
2,746
1,735
1,844
1,851
2,855
5,021
4,729
3,284
3,068
4,002
3,894
5,651
3,449
4,986
3,963
5,711
5,303
5,905
4,969
6,542
5,575
6,355
6,602
7,875
6,728
7,077
5,833
5,884
5,356
7,461
6,343
7,083
7,437
8,706
6,604
7,614
8,706
10,088
9,669
8,040
6,205
8,252
8,2526,2058,0409,66910,0888,7067,6146,6048,7067,4377,0836,3437,4615,3565,8845,8337,0776,7287,8756,6026,3555,5756,5424,9695,9055,3035,7113,9634,9863,4495,6513,8944,0023,0683,2844,7295,0212,8551,8511,8441,7352,7463,1952,3401,9731,7021,2791,6561,9481,9501,4312,0131,6771,5171,4571,9401,7581,379001,57502,19098084500
       Other Current Liabilities 
0
0
3,381
4,124
4,644
0
3,332
0
0
4,646
4,471
4,599
3,738
3,778
3,572
2,115
1,687
1,852
2,296
1,123
1,278
2,413
4,418
10,011
2,893
3,031
1,353
941
2,354
29,121
4,420
2,536
7,672
3,049
3,459
4,123
4,867
3,445
188
21
3,355
3,214
3,277
1,816
1,706
1,558
3,297
253
3,022
3,467
4,247
3,045
3,140
3,475
2,792
2,873
2,924
3,673
3,397
3,046
3,316
3,661
3,998
4,241
6,002
11,323
12,833
12,83311,3236,0024,2413,9983,6613,3163,0463,3973,6732,9242,8732,7923,4753,1403,0454,2473,4673,0222533,2971,5581,7061,8163,2773,2143,355211883,4454,8674,1233,4593,0497,6722,5364,42029,1212,3549411,3533,0312,89310,0114,4182,4131,2781,1232,2961,8521,6872,1153,5723,7783,7384,5994,4714,646003,33204,6444,1243,38100
   > Long-term Liabilities 
0
0
0
112,748
116,927
0
131,234
0
0
143,034
11,208
170,202
25
23
4,785
4,177
4,012
3,510
3,002
2,488
1,967
1,443
912
388
20,676
14,024
19,596
32,305
30,784
53,082
49,418
44,273
39,027
38,915
4,231
2,699
1,775
37,095
35,520
35,747
34,594
34,990
35,334
40,101
40,317
40,524
41,152
41,691
42,334
38,970
42,706
45,281
46,485
46,478
46,485
46,338
45,903
47,164
48,533
41,528
34,478
27,497
23,718
52,982
94,448
87,631
85,441
85,44187,63194,44852,98223,71827,49734,47841,52848,53347,16445,90346,33846,48546,47846,48545,28142,70638,97042,33441,69141,15240,52440,31740,10135,33434,99034,59435,74735,52037,0951,7752,6994,23138,91539,02744,27349,41853,08230,78432,30519,59614,02420,6763889121,4431,9672,4883,0023,5104,0124,1774,7852325170,20211,208143,03400131,2340116,927112,748000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,000
3,501
2,868
2,332
1,793
1,250
703
153
3,889
3,472
3,194
2,778
9,313
33,938
33,065
29,808
26,688
34,448
582
561
486
33,826
33,358
33,593
33,821
34,215
34,568
37,537
37,461
37,663
38,178
38,080
38,288
35,298
38,658
41,395
42,510
42,459
42,408
42,352
42,595
0
0
0
0
0
0
0
63,954
0
0
0063,954000000042,59542,35242,40842,45942,51041,39538,65835,29838,28838,08038,17837,66337,46137,53734,56834,21533,82133,59333,35833,82648656158234,44826,68829,80833,06533,9389,3132,7783,1943,4723,8891537031,2501,7932,3322,8683,5014,0000000000000000000
       Deferred Long Term Asset Charges 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
223
233
227
230
0
443
474
489
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000048947444302302272332230000000000000000000000000000000000
       Warrants
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
415
415
415
415
415
415
415
415
461
417
412
219
968
1,497
1,497
1,497
1,497
1,497
2,747
3,049
3,049
3,338
3,707
3,707
3,707
3,707
3,707
3,707
3,707
3,707
3,707
3,707
3,707
3,707
3,707
3,707
3,707
3,707
370
370
370
0
0
0
0
0
0
0
0
0
0
00000000003703703703,7073,7073,7073,7073,7073,7073,7073,7073,7073,7073,7073,7073,7073,7073,7073,7073,3383,0493,0492,7471,4971,4971,4971,4971,4979682194124174614154154154154154154154150000000000000000
       Other Liabilities 
0
0
15
72
0
0
13,211
0
0
0
37,409
37,431
25
23
18
15
12
9
128
156
174
193
209
235
16,787
10,552
16,402
29,527
21,471
19,144
16,353
14,465
12,339
4,467
3,649
2,138
1,289
3,269
2,162
2,154
773
775
766
2,564
2,518
2,497
2,974
2,810
2,824
2,783
3,125
3,124
3,127
3,125
3,563
3,535
3,308
4,326
2,718
2,484
5,181
5,005
0
0
28,285
0
0
0028,285005,0055,1812,4842,7184,3263,3083,5353,5633,1253,1273,1243,1252,7832,8242,8102,9742,4972,5182,5647667757732,1542,1623,2691,2892,1383,6494,46712,33914,46516,35319,14421,47129,52716,40210,55216,7872352091931741561289121518232537,43137,40900013,21100721500
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11,376
3,013
0
1,296
472
1,060
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000001,0604721,29603,01311,37600000000000000000000000000000000
> Total Stockholder Equity
0
0
0
-82,469
-89,696
0
-115,887
0
0
-141,176
-5,382
-166,495
56,298
50,444
45,212
41,065
36,650
30,585
24,978
20,969
16,851
11,797
39,144
25,736
9,971
9,198
-4,925
10,651
13,659
8,223
49,519
40,572
33,331
33,361
26,320
16,893
11,803
30,032
25,586
20,066
21,702
20,764
14,919
8,551
5,538
2,971
2,722
646
-3,682
-6,476
-4,445
-5,404
-7,530
-7,633
-7,978
-11,960
5,891
1,502
-2,605
-8,603
-12,335
-18,078
-20,848
-18,916
46,230
48,840
46,170
46,17048,84046,230-18,916-20,848-18,078-12,335-8,603-2,6051,5025,891-11,960-7,978-7,633-7,530-5,404-4,445-6,476-3,6826462,7222,9715,5388,55114,91920,76421,70220,06625,58630,03211,80316,89326,32033,36133,33140,57249,5198,22313,65910,651-4,9259,1989,97125,73639,14411,79716,85120,96924,97830,58536,65041,06545,21250,44456,298-166,495-5,382-141,17600-115,8870-89,696-82,469000
   Common Stock
0
0
52
52
52
0
51
0
0
52
283
56
351
351
313
313
314
314
314
314
314
315
315
316
316
316
316
380
403
443
443
444
444
445
450
450
454
647
649
649
670
691
691
700
700
700
701
710
710
710
50
50
50
51
57
58
69
69
69
70
70
70
70
74
88
524
524
52452488747070707069696958575150505071071071070170070070069169167064964964745445045044544444444344340338031631631631631531531431431431431431331335135156283520051052525200
   Retained Earnings Total Equity00-412,7790000000-388,992-396,557-392,909-391,932-391,314-388,768-387,570-388,068-384,928-379,890-377,127-375,879-410,758-406,758-399,075-391,851-386,566-383,809-377,074-371,146-361,903-355,044-343,900-333,187-331,644-323,048-313,255-303,997-296,989-298,104-277,345-262,573-261,463-245,100-231,116-225,827-220,433-215,731-211,370-205,299-198,7590000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
-420
-483
0
-611
0
0
-798
-848
-36,907
0
0
-1,028
-1,028
0
0
-1,000
-1,000
0
0
-1,106
8
45
-225
-488
-484
-345
-663
-812
-1,170
-1,100
-1,060
-1,148
-1,029
-1,099
-1,069
-1,272
-1,223
-997
-879
-821
-715
-928
-954
-1,011
-1,094
-1,039
-1,204
-1,093
-1,179
-1,086
-888
-553
-1,150
-1,117
-1,568
-1,849
-2,205
-3,128
-3,772
-2,995
-2,783
-2,783
-2,994
1,690
1,690-2,994-2,783-2,783-2,995-3,772-3,128-2,205-1,849-1,568-1,117-1,150-553-888-1,086-1,179-1,093-1,204-1,039-1,094-1,011-954-928-715-821-879-997-1,223-1,272-1,069-1,099-1,029-1,148-1,060-1,100-1,170-812-663-345-484-488-225458-1,10600-1,000-1,00000-1,028-1,02800-36,907-848-79800-6110-483-420000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
234,680
235,155
235,619
235,971
236,555
236,894
237,485
238,052
238,567
239,218
240,135
276,595
282,384
291,716
292,851
294,054
295,339
296,871
299,376
300,672
302,507
329,467
330,781
331,947
336,093
340,301
341,622
342,822
344,022
345,053
346,108
346,869
347,524
348,035
350,117
350,442
350,769
352,728
365,830
366,092
376,334
0
0
0
0
0
0
0
386,979
0
0
00386,9790000000376,334366,092365,830352,728350,769350,442350,117348,035347,524346,869346,108345,053344,022342,822341,622340,301336,093331,947330,781329,467302,507300,672299,376296,871295,339294,054292,851291,716282,384276,595240,135239,218238,567238,052237,485236,894236,555235,971235,619235,155234,6800000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
3,376
3,495
0
4,143
0
0
6,666
165,465
5,147
232,466
232,694
234,781
234,303
235,095
235,570
237,034
236,386
236,970
237,309
239,006
238,467
239,028
239,635
240,548
276,814
283,352
293,213
294,348
295,551
296,836
298,368
302,123
303,721
305,556
332,805
334,488
335,654
339,800
344,008
345,329
346,529
347,729
348,760
349,815
350,576
351,231
351,742
353,824
354,149
354,476
356,435
366,200
366,462
376,704
376,949
377,229
377,541
377,847
378,005
378,238
378,146
386,979
461,622
458,574
458,574461,622386,979378,146378,238378,005377,847377,541377,229376,949376,704366,462366,200356,435354,476354,149353,824351,742351,231350,576349,815348,760347,729346,529345,329344,008339,800335,654334,488332,805305,556303,721302,123298,368296,836295,551294,348293,213283,352276,814240,548239,635239,028238,467239,006237,309236,970236,386237,034235,570235,095234,303234,781232,694232,4665,147165,4656,666004,14303,4953,376000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue80,754
Cost of Revenue-19,584
Gross Profit61,17061,170
 
Operating Income (+$)
Gross Profit61,170
Operating Expense-62,641
Operating Income-1,471-1,471
 
Operating Expense (+$)
Research Development16,626
Selling General Administrative18,530
Selling And Marketing Expenses27,946
Operating Expense62,64163,102
 
Net Interest Income (+$)
Interest Income0
Interest Expense-10,185
Other Finance Cost-3,120
Net Interest Income-7,065
 
Pretax Income (+$)
Operating Income-1,471
Net Interest Income-7,065
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-20,04717,105
EBIT - interestExpense = -11,656
-20,047
-9,947
Interest Expense10,185
Earnings Before Interest and Taxes (EBIT)-1,471-9,862
Earnings Before Interest and Taxes (EBITDA)7,276
 
After tax Income (+$)
Income Before Tax-20,047
Tax Provision-77
Net Income From Continuing Ops-20,131-20,124
Net Income-20,132
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses82,225
Total Other Income/Expenses Net-18,5767,065
 

Technical Analysis of Alimera Sciences Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Alimera Sciences Inc. The general trend of Alimera Sciences Inc is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Alimera Sciences Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Alimera Sciences Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3.71 < 3.725 < 4.25.

The bearish price targets are: 3.07 > 2.95 > 2.9314.

Tweet this
Alimera Sciences Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Alimera Sciences Inc. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Alimera Sciences Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Alimera Sciences Inc. The current macd is -0.09310295.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Alimera Sciences Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Alimera Sciences Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Alimera Sciences Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Alimera Sciences Inc Daily Moving Average Convergence/Divergence (MACD) ChartAlimera Sciences Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Alimera Sciences Inc. The current adx is 19.67.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Alimera Sciences Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Alimera Sciences Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Alimera Sciences Inc. The current sar is 3.7.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Alimera Sciences Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Alimera Sciences Inc. The current rsi is 45.28. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Alimera Sciences Inc Daily Relative Strength Index (RSI) ChartAlimera Sciences Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Alimera Sciences Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Alimera Sciences Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Alimera Sciences Inc Daily Stochastic Oscillator ChartAlimera Sciences Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Alimera Sciences Inc. The current cci is -65.04940351.

Alimera Sciences Inc Daily Commodity Channel Index (CCI) ChartAlimera Sciences Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Alimera Sciences Inc. The current cmo is -7.89114234.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Alimera Sciences Inc Daily Chande Momentum Oscillator (CMO) ChartAlimera Sciences Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Alimera Sciences Inc. The current willr is -54.16666667.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Alimera Sciences Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Alimera Sciences Inc Daily Williams %R ChartAlimera Sciences Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Alimera Sciences Inc.

Alimera Sciences Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Alimera Sciences Inc. The current atr is 0.23066413.

Alimera Sciences Inc Daily Average True Range (ATR) ChartAlimera Sciences Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Alimera Sciences Inc. The current obv is 38,795,851.

Alimera Sciences Inc Daily On-Balance Volume (OBV) ChartAlimera Sciences Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Alimera Sciences Inc. The current mfi is 18.54.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Alimera Sciences Inc Daily Money Flow Index (MFI) ChartAlimera Sciences Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Alimera Sciences Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-14MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-02RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-17CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-18CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-31CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-05WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-13MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-15CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23MFI SHORT ENTRY LONG CLOSE20 crossover to downside

6.3. Candlestick Patterns

Alimera Sciences Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Alimera Sciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.276
Ma 20Greater thanMa 503.723
Ma 50Greater thanMa 1003.716
Ma 100Greater thanMa 2003.763
OpenGreater thanClose3.573
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Alimera Sciences Inc with someone you think should read this too:
  • Are you bullish or bearish on Alimera Sciences Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Alimera Sciences Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Alimera Sciences Inc

I send you an email if I find something interesting about Alimera Sciences Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Alimera Sciences Inc.

Receive notifications about Alimera Sciences Inc in your mailbox!